The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

Investing.com -- Gilead Sciences (NASDAQ: GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE: CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

E xecutives at Gilead Sciences, the biotech behind a long list of HIV treatments and preventative medicines, have spoken with great optimism in recent weeks about the prospects that insurers will ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

W hen drugmaker Gilead Sciences announced interim late-stage trial results of its injectable HIV prevention drug last month, researchers, advocates and Wall Street collectively rejoiced.

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

F ollowing the release of widely touted study results for a Gilead Sciences HIV treatment, a new analysis finds the medicine — called lenacapavir — could be made for as little as $26 to $40 ...

Market Catalysts Host Julie Hyman recaps some of the trending tickers on Thursday, Aug. 21, including Coty (COTY), Gilead ...

Gilead's longtime goal has been to develop a cure for HIV. And now the biotech doesn't just have one pipeline candidate in clinical testing that could achieve that goal -- it has four.